JonesResearch analyst Soumit Roy downgraded CervoMed (CRVO) to Hold from Buy without a price target after the company’s Phase 2b trial in dementia with Lewy bodies did not meet the primary and secondary endpoints. Neflamapimod did not demonstrate statistically significant effects compared to placebo on primary and secondary endpoints at 16 weeks, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.